Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole

Giladi, Nir, Boroojerdi, Babak, Korczyn, Amos D., Burn, David J., Clarke, Carl E., Schapira, Anthony H.V., SP513 investigators·2007·Movement Disorders

Abstract

Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine, ropinirole, or placebo. The titration period was up to 13 weeks, and there was a minimum dose‐maintenance period of 24 weeks for ropinirole and 33 weeks for rotigotine. The primary endpoint was the proportion of patients with a minimum of 20% decrease in the combined Unified Parkinson's Disease Rating Scale Part II and Part III scores. The responder rate in the rotigotine group was significantly higher than in the placebo group (52% vs. 30%, P < 0.0001). Transdermal rotigotine at doses ≤8 mg/24 h did not show noninferiority to ropinirole at doses ≤24 mg/day. In a post‐hoc subgroup analysis, rotigotine ≤8 mg/24 hours had a similar efficacy to ropinirole at doses ≤12 mg/day. The rotigotine transdermal patch was well tolerated. The most common adverse events were application‐site reactions, nausea, and somnolence. Application‐site reactions were predominantly mild or moderate in intensity. In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.21741

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 227

Metadata

Authors
Giladi, N., Boroojerdi, B., Korczyn, A. D., Burn, D. J., Clarke, C. E., Schapira, A. H. V., & SP513 investigators
Venue
Movement Disorders
Publisher
Wiley
Published
2007-12-15
Volume
22
Issue
16
Pages
2398-2404
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W2098749010
Cited by
227
References
2
FWCI
7.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole. https://app.cochat.ai/papers/10.1002/mds.21741
The paper
Giladi, N., Boroojerdi, B., Korczyn, A. D., Burn, D. J., Clarke, C. E., Schapira, A. H. V., & SP513 investigators. (2007). Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole. Movement Disorders. https://doi.org/10.1002/mds.21741

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.